A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

Oncogene

Volumn 34, Issue 27, 2015, Pages 3547-3555

  Kasinski, A L ^a,b   Kelnar, K ^c   Stahlhut, C ^a   Orellana, E ^b   Zhao, J ^c   Shimer, E ^a   Dysart, S ^c   Chen, X ^a   Bader, A G ^c   Slack, F J ^a,d  

^a YALE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c SYNLOGIC   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; K RAS PROTEIN; LET 7B PROTEIN; MICRORNA 34A; PROTEIN; PROTEIN P53; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MICRORNA; MIRN34 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN; NANOMATERIAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; GENE REPRESSION; GENE THERAPY; IN VIVO STUDY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; SYSTEMIC THERAPY; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; GENES, TUMOR SUPPRESSOR; GENETIC THERAPY; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MICRORNAS; NANOSTRUCTURES; TUMOR BURDEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84986587264     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.282     Document Type: Article

References (34)

1. National Lung Screening Trial Research Team, Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM et al. The National Lung Screening Trial: overview and study design. Radiology 2011;258:243-253.
2. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-198.
3. Lin P-Y, Yu S-L, Yang P-C. MicroRNA in lung cancer. Br J Cancer 2010;103:1144-1148.
4. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-647.
5. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-3756.
6. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:1298-1307.
7. Lodygin D, Lodygin D, Tarasov V, Tarasov V, Epanchintsev A, Epanchintsev A et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008;7:2591-2600.
8. Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009;30:1903-1909.
9. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-1030.
10. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67:9762-9770.
11. Wei JS, Song YK, Durinck S, Chen Q-R, Cheuk ATC, Tsang P et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008;27:5204-5213.
12. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-1134.
13. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-1593.
14. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26:731-743.
15. Chang T-C, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745-752.
16. Zhao J, Lammers P, Torrance CJ, Bader AG. TP53-independent function of miR-34a via HDAC1 and p21 (CIP1/WAF1.). Mol Ther 2013;21:1678-1686.
17. Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011;11:849-864.
18. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 1999;216:671-680.
19. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 2004;15:185-197.
20. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science 2008;320:97-100.
21. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008;7:759-764.
22. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2009;29:1580-1587.
23. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008;105:3903-3908.
24. Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 2012;72:5576-5587.
25. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010;70:5923-5930.
26. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19:1116-1122.
27. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010;28:585-593.
28. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protoc 2009;4:1064-1072.
29. Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R et al. Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 2011;1:236-247.
30. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-906.
31. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008;14:1539-1549.
32. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012;3:120.
33. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013;31:577.
34. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-675.